0000899243-22-016387.txt : 20220503
0000899243-22-016387.hdr.sgml : 20220503
20220503174906
ACCESSION NUMBER: 0000899243-22-016387
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220429
FILED AS OF DATE: 20220503
DATE AS OF CHANGE: 20220503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woiwode Thomas
CENTRAL INDEX KEY: 0001619294
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 22888645
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tempest Therapeutics, Inc.
CENTRAL INDEX KEY: 0001544227
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 451472564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT
STREET 2: SUITE 275
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-798-8589
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT
STREET 2: SUITE 275
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Millendo Therapeutics, Inc.
DATE OF NAME CHANGE: 20181207
FORMER COMPANY:
FORMER CONFORMED NAME: OvaScience, Inc.
DATE OF NAME CHANGE: 20120308
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-29
0
0001544227
Tempest Therapeutics, Inc.
TPST
0001619294
Woiwode Thomas
7000 SHORELINE COURT
SUITE 275
SOUTH SAN FRANCISCO
CA
94080
1
0
1
0
Common Stock
2022-04-29
4
P
0
2118644
2.36
A
2118644
I
See Footnote
Common Stock
997940
I
See Footnote
Common Stock
1171094
I
See Footnote
Common Stock
7377
I
See Footnote
Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. ("Vantage II") and certain other investors.
These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
/s/ Robin Praeger, attorney-in-fact for Thomas Woiwode
2022-05-03